ORBi: Detailled Reference

Article (Scientific journals)

Le sepsis, réponse adaptée ou non à l’infection?

Damas, Pierre

2009 • In Réanimation, 18 (4), p. 277-281

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/72649

DOI
10.1016/j.reaurg.2009.03.001

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

98.pdf

Publisher postprint (376.74 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Sepsis; Inflammation; Choc septique; Facteurs de virulence

Abstract :

[en] Sepsis, severe sepsis and septic shock were thought to be provoked by an overwhelming inflammation in response to an infectious process. This was documented in several animal studies. However, in human sepsis, excess of inflammation is hard to be observed. Compartimentalization of the host response rather favors a systemic anti-inflammatory climate. Clinical situations are complex: on one hand, virulence factors of microorganisms can directly harm the host tissues, divert the defence mechanisms or distract the control mechanisms of the host, preventing the normal interaction of endogenous mediators. On the other hand, septic shock mostly occurs in patients experiencing previous organic or functional vital failures before the development of infection. The vulnerability of the patient appears therefore to be a key point in the severity of the disease. Enhancing the host defence mechanisms rather than inhibiting the inflammatory reaction may become a preferential option.

Disciplines :

Anesthesia & intensive care

Author, co-author :

Damas, Pierre ; Université de Liège - ULiège > Soins intensifs

Language :

French

Title :

Le sepsis, réponse adaptée ou non à l’infection?

Alternative titles :

[en] Sepsis, adaptive or maladaptive response to infection?

Publication date :

2009

Journal title :

Réanimation

ISSN :

1624-0693

eISSN :

1951-6959

Publisher :

Elsevier, Netherlands

Volume :

18

Issue :

4

Pages :

277-281

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 22 September 2010

Statistics

Number of views

55 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

1

Scopus citations^®
without self-citations

1

OpenCitations

1

OpenAlex citations

1

Bibliography

Morrison D. Bacterial endotoxins and pathogenesis. Rev Infect Dis 5 Suppl. 4 (1983) S733-S747
Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
Girardin E., Grau G.E., Dayer J.M., Roux-Lombard P., and The J5 study group. Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319 (1988) 397-400
Bone R., Grodzin C., and Balk R. Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 112 (1997) 235-243
Abraham E., and Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35 (2007) 2408-2416
Beutler B., Milsark I.W., and Cerami A. Cachectin, tumor necrosis factor: production, distribution and metabolic fate in vivo. J Immunol 135 (1985) 3972-3977
Marks J.D., Berman Marks C., Luce J.M., Montgomery A.B., Turner J., et al. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Resp Dis 141 (1990) 94-97
Van Deventer S.J.H., Buller H.R., Ten Cate J.W., Aarden L.A., Hack C.E., and Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76 (1990) 2520-2526
Waage A., Brandtzaeg P., Haltensen A., Kierulf P., and Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between Interleukin 6, Interleukin 1, and fatal outcome. J Exp Med 169 (1989) 333-338
Damas P., Ledoux D., Nys M., Vrindts Y., De Groote D., Franchimont P., et al. Cytokine serum levels during severe sepsis in human. IL6 as a marker of severity. Ann Surg 215 (1992) 356-362
Goldie A.S., Fearon K.C.H., Ross J.A., Barclay R., Jackson R.E., Grant I.S., et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274 (1995) 172-177
Kellum J.A., Kong L., Fink M.P., Weissfeld L.A., Yealy D.M., Pinsky M., et al. Understanding the inflammatory cytokine response in pneumonia and sepsis. Arch Int Med 167 (2007) 1655-1663
Remick D.G., and Ward P. Evaluation of endotoxin models for the study of sepsis. Shock 24 (2005) S7-11
Cohen J., and Carlet J. Intersept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 24 (1996) 1431-1440
Abraham E., Anzueto A., Gutierez G., Tessler S., San Pedro G., Wunderink R., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 351 (1998) 929-933
Reinhart K., Menges T., Gardlund B., Zwaveling J.H., Smithes M., Vincent J.L., et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Crit Care Med 29 (2001) 765-769
Panacek E.A., Marshall J.C., Albertson T.E., Johnson D.H., Johnson S., Macarthur R.D., et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32 (2004) 2173-2182
Abraham E., Laterre P.F., Garbino J., Pingleton S., Butler T., Dugernier T., et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1342 patients. Crit Care Med 29 (2001) 503-510
Fisher C.J., Agost J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334 (1996) 1697-1702
Fekade D., Knox M.B., Hussein K., Melka A., Lalloo D.G., Coxon R.E., et al. Prevention of Jarisch-Herxheimer reaction by treatment with antibodies against tumor necrosis factor-alpha. N Engl J Med 335 (1996) 311-315
Poli-de-Figueiredo L., Garrido A.G., Nakagawa N., and Sannomiya P. Experimental models of sepsis and their clinical relevance. Shock 30 (2008) S53-S59
Eskanderi M.K., Bolgos G., Miller C., Nguyen D.T., DeForge L.E., and Remick D.G. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148 (1992) 2724-2730
Echtenacher B., Weigl K., Lehn N., and Mannel D.N. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 69 (2001) 3550-3555
Bagby G.J., Plessala K.J., Wilson A., Thompson J.J., and Nelson S. Divergent efficacy of antibody to tumor necrosis factor alpha in intravascular and peritonitis models of sepsis. J Infect Dis 163 (1991) 83-88
Shapiro N., Howell M.D., Bates D.W., Angus D.C., Ngo L., and Talmor D. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med 48 (2006) 583-590
Alberti C., Brun-Buisson C., Burchardi H., Martin C., Goodman S., Artigas A., et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28 (2002) 108-121
Moore F.A., and Moore E.E. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 75 (1995) 257-277
Saadia R., and Schein M. Multiple organ failure. How valid is the "two hit" model?. J Accid Emerg Med 16 (1999) 163-167
Monneret G., Venet F., Pachot A., and Lepape A. Monitoring immune dysfunctions in the septic patients: a new skin for the old ceremony. Mol Med 14 (2008) 64
Adib-Conquy M., and Cavaillon J.M. Compensatory anti-inflammatory response syndrome. Thromb Haemost 101 (2009) 36-47
Damas P., Ledoux D., Nys M., Monchi M., Wiesen P., Beauve B., et al. Intensive Care unit acquired infection and organ failure. Intensive Care Med 34 (2008) 856-864
Annane D., Sebille V., Charpentier C., Bollaert P.E., François B., Korach J.M., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
Sprung C.L., Annane D., Keh D., Moreno R., Singer M., Freivogel K., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 (2008) 111-124
Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., and Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 (1995) 117-123
Beutler B., Jiang Z., Georgel P., Crozat K., Croker B., Rutschmann S., et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 24 (2006) 353-389
Headley A.J. Necrotizing soft tissue infections: a primary care review. Am Fam Physician 68 (2003) 323-328
Parry C.M., Hien T.T., Dougan G., White N.J., and Farrar J.J. Typhoid fever. N Engl J Med 347 (2002) 1770-1782
Francis J.S., Doherty M.C., Lopatin U., Johnston C.P., Sinha G., Ross T., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40 (2005) 100-107
El Solh A.A., Akinnusi M.E., Wiener-Kronish J.P., Lynch S.V., Pineda L.A., and Szarpa K. Persistent infection with Pseudomonas aeruginosa in ventilator associated pneumonia. Am J Resp Crit Care Med 178 (2008) 513-519
Sjöström K., Spindler C., Ortqvist A., Kalin M., Sandgren A., and Kühlmann-Berenzon S. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 42 (2006) 451-459
Fast D.L., Schlievert P.M., and Nelson R.D. Toxic shock syndrome-associated staphylococcal and streptococcal toxins are potent inducers of tumour necrosis factor production. Infect Immun 57 (1989) 291-294
Brown E.J. The molecular basis of streptococcal toxic shock syndrome. N Engl J Med 350 (2004) 2093-2094
Nelson S., Belknap S.M., Carlson R.W., Dale D., DeBoisblanc B., Farkas S., et al. A randomized controlled trial of filgastrim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study group. J Infect Dis 178 (1998) 1075-1080
Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp 280 (2007) 21-27
Cinel I., and Opal S.M. Molecular biology of inflammation and sepsis: A primer. Crit Care Med 37 (2009) 291-304

Similar publications